Showing 5591-5600 of 7301 results for "".
- Obagi Launches SKINCLUSION Initiative to Celebrate Diversity with Brand Ambassador Priyanka Chopra Jonashttps://practicaldermatology.com/news/obagi-launches-skinclusion-initiative-to-celebrate-diversity-with-brand-ambassador-and-priyanka-chopra-jonas/2460026/Obagi kicked off its SKINCLUSION initiative, designed to elevate the global dialogue about diversity and how we can all make conscious choices to see the beauty in all of our differences, with an event in New York City introducing Priyanka Chopra Jonas as its SKINCLUSION ambassador. Priyanka, an
- Sensus Healthcare Awarded Brachytherapy Products Agreement with Premierhttps://practicaldermatology.com/news/sensus-healthcare-awarded-brachytherapy-products-agreement-with-premier/2460025/Sensus Healthcare, Inc.has been awarded a group purchasing agreement for Brachytherapy Products with Premier. Effective August 1, 2019, the new agreement allows Premier members, at their discretion, to take advantage of special pricing and terms pre-negotiated by Premier for Sensus’ SRT-100
- Aesthetic Innovations Summit Coming to New Orleanshttps://practicaldermatology.com/news/aesthetic-innovations-summit-coming-to-new-orleans/2460022/Coming off an impressive inaugural meeting in 2018, the second annual Aesthetics Innovation Summit will unite over 300 of the most influential corporate, capital, and clinical leaders in New Orleans to collaborate on the development and adoption of new aesthetic treatments and technologies.
- AAD: Half of Americans Aren't Protecting Themselves from the Sunhttps://practicaldermatology.com/news/aad-half-of-americans-arent-protecting-themselves-from-the-sun/2460018/Most Americans aren’t using sun protection as often as they should be —increasing their risk for skin cancer, including melanoma. In fact, just half of Americans always or almost always protect themselves from the sun when they’re outside, according to a new survey by
- Crown Labs Adds to Portfolio with Acquisition of Keri from GSKhttps://practicaldermatology.com/news/crown-labs-adds-to-portfolio-with-acquisition-of-keri-from-gsk/2460017/Crown Laboratories, Inc. acquired the North American rights for Keri from GlaxoSmithKline (GSK). The acquisition of Keri from GSK marks the sixth product from GSK that Crown has acquired in the past five months. “Acqui
- Happy 10th Birthday Dysport!https://practicaldermatology.com/news/happy-10th-birthday-dysport/2460015/Galderma Laboratories’ Dysport (abobotulinumtoxinA) is ringing in its 10th birthday. To celebrate this milestone, Galderma is offering double points for Dysport aesthetic treatments registered in the ASPIRE Rewards program through July 31
- Higher BMI Linked to Psoriasishttps://practicaldermatology.com/news/higher-bmi-linked-to-psoriasis/2460014/Excess weight is a contributing factor for developing psoriasis, and the greater the body mass index (BMI), the higher the chance of getting the disease, according to a new study. To investigate the causal relationship between BMI and psoriasis, the researchers used Mendelian randomizat
- Five-Year Retrospective Study Shows 98.9 Percent Cure Rate for NMSC Patients Treated with Superficial Radiation Therapyhttps://practicaldermatology.com/news/five-year-retrospective-study-shows-989-percent-cure-rate-for-nmsc-patients-treated-with-superficial-radiation-therapy/2460013/Sensus Healthcare, Inc. shared topline results from a five-year retrospective study of non-melanoma ski
- SkinBioTherapeutics Names New Executive Directorhttps://practicaldermatology.com/news/skinbiotherapeutics-names-new-executive-director/2460012/Stuart Ashman is the new executive director of SkinBioTherapeutics. Mr. Ashman will succeed Professor Cath O’Neill as CEO after a period of transition. Ms. O’Neill will continue to drive the science and the ongoing commercial
- Study Highlights Adverse Events Associated with Energy-Based Vaginal Rejuvenationhttps://practicaldermatology.com/news/study-highlights-adverse-events-associated-with-energy-based-vaginal-rejuvenation/2460010/Concerns from the federal Food and Drug Administration (FDA) sired the first assessment of adverse events related to device-based procedures marketed for ‘vaginal rejuvenation,’ and the new analysis of the Manufacturer and User Facility Device Experience (MAUDE) database identified a